ELOX Eloxx Pharmaceuticals Inc

Price (delayed)

$1.35

Market cap

$64.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$60.48M

Highlights
The EPS has increased by 46% YoY and by 15% QoQ
ELOX's net income is up by 45% year-on-year and by 15% since the previous quarter
The debt has increased by 10% since the previous quarter but it has declined by 10% year-on-year
Eloxx Pharmaceuticals's equity has plunged by 90% YoY and by 73% from the previous quarter
The company's quick ratio has shrunk by 64% YoY and by 43% QoQ

Key stats

What are the main financial stats of ELOX
Market
Shares outstanding
47.86M
Market cap
$64.61M
Enterprise value
$60.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
19.74
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$29.33M
EBITDA
-$28.73M
Free cash flow
-$23.93M
Per share
EPS
-$0.73
Free cash flow per share
-$0.6
Book value per share
$0.07
Revenue per share
$0
TBVPS
$0.51
Balance sheet
Total assets
$20.37M
Total liabilities
$17.62M
Debt
$14.18M
Equity
$2.75M
Working capital
$7.27M
Liquidity
Debt to equity
5.15
Current ratio
1.57
Quick ratio
1.44
Net debt/EBITDA
0.14
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-98%
Return on equity
-242.6%
Return on invested capital
-407.2%
Return on capital employed
-382.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ELOX stock price

How has the Eloxx Pharmaceuticals stock price performed over time
Intraday
3.85%
1 week
-1.46%
1 month
-30.41%
1 year
-59.34%
YTD
-66.08%
QTD
-32.16%

Financial performance

How have Eloxx Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.1M
Net income
-$29.33M
Gross margin
N/A
Net margin
N/A
Eloxx Pharmaceuticals's operating income has increased by 46% YoY and by 16% from the previous quarter
ELOX's net income is up by 45% year-on-year and by 15% since the previous quarter

Growth

What is Eloxx Pharmaceuticals's growth rate over time

Valuation

What is Eloxx Pharmaceuticals stock price valuation
P/E
N/A
P/B
19.74
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 46% YoY and by 15% QoQ
The stock's P/B is 100% more than its 5-year quarterly average of 9.5
Eloxx Pharmaceuticals's equity has plunged by 90% YoY and by 73% from the previous quarter

Efficiency

How efficient is Eloxx Pharmaceuticals business performance
The company's return on invested capital has shrunk by 191% YoY and by 50% QoQ
Eloxx Pharmaceuticals's ROE has plunged by 87% YoY and by 26% from the previous quarter
The ROA is down by 17% year-on-year and by 3.7% since the previous quarter

Dividends

What is ELOX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELOX.

Financial health

How did Eloxx Pharmaceuticals financials performed over time
The total assets is 16% greater than the total liabilities
The company's quick ratio has shrunk by 64% YoY and by 43% QoQ
The current ratio has dropped by 62% year-on-year and by 40% since the previous quarter
Eloxx Pharmaceuticals's equity has plunged by 90% YoY and by 73% from the previous quarter
The debt has increased by 10% since the previous quarter but it has declined by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.